TY - JOUR
T1 - Comparison of chemotherapeutic agents as a myeloablative conditioning with total body irradiation for pediatric acute lymphoblastic leukemia
T2 - A study from the pediatric ALL working group of the Japan Society for Hematopoietic Cell Transplantation
AU - Kato, Motohiro
AU - Ishida, Hiroyuki
AU - Koh, Katsuyoshi
AU - Inagaki, Jiro
AU - Kato, Keisuke
AU - Goto, Hiroaki
AU - Kaneko, Takashi
AU - Cho, Yuko
AU - Hashii, Yoshiko
AU - Kurosawa, Hidemitsu
AU - Takita, Junko
AU - Hamamoto, Kazuko
AU - Inoue, Masami
AU - Sawada, Akihisa
AU - Suzuki, Ritsuro
AU - Kato, Koji
N1 - Publisher Copyright:
© 2015 Wiley Periodicals, Inc.
Copyright:
Copyright 2015 Elsevier B.V., All rights reserved.
PY - 2015/10/1
Y1 - 2015/10/1
N2 - Background: As a partner of total body irradiation (TBI) in hematopoietic stem cell transplantation (HSCT) for pediatric acute lymphoblastic leukemia (ALL), various cytotoxic agents are used, but the optimal combination is still unclear. Procedure: We retrospectively analyzed 767 children who received TBI-based myeloablative allogeneic HSCT in complete remission (CR), using nationwide registry data of the Japan Society for Hematopoietic Cell Transplantation. Combinations of chemotherapy were categorized as follows: cyclophosphamide (CY) (n=74), melphalan (L-PAM) (n=139), CY+etoposide (VP16) (n=408), CY+cytarabine (AraC) (n=73), and others (n=73). Results: Event-free survival (EFS) at 5 years after HSCT was 62.2% for CY, 71.4% for L-PAM, 67.6% for CY+VP16, 52.6% for CY+AraC, and 59.1% for others (P=0.009). Further detailed comparison of LPAM and CY+VP16 demonstrated superior EFS for LPAM (83.2±6.7%), with a marked difference compared with CY+VP16 (66.7±4.9%) when limited to HSCT from a matched related donor (MRD), and this result was reproduced regardless of disease status (CR1 or CR2). However, EFS for CY+VP16 (68.3±2.8%) was comparable to that for LPAM (64.5±5.7%, P=0.37) in HSCT from alternative donors, because higher non-relapse mortality attenuated the advantage of LPAM. Conclusions: For pediatric ALL in remission, LPAM could provide superior EFS for HSCT from MRD; however, compared to LPAM, CY+VP16 has similar EFS for HSCT from an alternative donor.
AB - Background: As a partner of total body irradiation (TBI) in hematopoietic stem cell transplantation (HSCT) for pediatric acute lymphoblastic leukemia (ALL), various cytotoxic agents are used, but the optimal combination is still unclear. Procedure: We retrospectively analyzed 767 children who received TBI-based myeloablative allogeneic HSCT in complete remission (CR), using nationwide registry data of the Japan Society for Hematopoietic Cell Transplantation. Combinations of chemotherapy were categorized as follows: cyclophosphamide (CY) (n=74), melphalan (L-PAM) (n=139), CY+etoposide (VP16) (n=408), CY+cytarabine (AraC) (n=73), and others (n=73). Results: Event-free survival (EFS) at 5 years after HSCT was 62.2% for CY, 71.4% for L-PAM, 67.6% for CY+VP16, 52.6% for CY+AraC, and 59.1% for others (P=0.009). Further detailed comparison of LPAM and CY+VP16 demonstrated superior EFS for LPAM (83.2±6.7%), with a marked difference compared with CY+VP16 (66.7±4.9%) when limited to HSCT from a matched related donor (MRD), and this result was reproduced regardless of disease status (CR1 or CR2). However, EFS for CY+VP16 (68.3±2.8%) was comparable to that for LPAM (64.5±5.7%, P=0.37) in HSCT from alternative donors, because higher non-relapse mortality attenuated the advantage of LPAM. Conclusions: For pediatric ALL in remission, LPAM could provide superior EFS for HSCT from MRD; however, compared to LPAM, CY+VP16 has similar EFS for HSCT from an alternative donor.
UR - http://www.scopus.com/inward/record.url?scp=84939571740&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84939571740&partnerID=8YFLogxK
U2 - 10.1002/pbc.25602
DO - 10.1002/pbc.25602
M3 - Article
C2 - 26053959
AN - SCOPUS:84939571740
VL - 62
SP - 1844
EP - 1850
JO - Pediatric Blood and Cancer
JF - Pediatric Blood and Cancer
SN - 1545-5009
IS - 10
ER -